Abstract:BACKGROUND: In China, standard neoadjuvant chemoradiation therapy has not been well accepted, not only because of financial constraints but also because of the poorly-tolerated long duration of the regimen.OBJECTIVE: The current study aimed to evaluate the impact of a modified neoadjuvant radiation regimen on the prognosis of rectal cancer patients in China.DESIGN: This was a nonrandomized cohort study evaluating outcomes of patients who chose to undergo preoperative radiotherapy compared with those who chose not to undergo preoperative radiotherapy (controls).SETTINGS: The study was carried out in Peking University Cancer Hospital, a tertiary care cancer center in China.PATIENTS: Records of patients with locally advanced, mid-to-low rectal cancer who underwent total mesorectal excision at Peking University Cancer Hospital from 2001 through 2005 were analyzed in this study.INTERVENTION: Patients who chose preoperative radiotherapy received a total dose of 30 Gy delivered in 10 once-daily fractions of 3.0 Gy each, with at least a 14-day delay of surgery after delivery of the last fraction.MAIN OUTCOME MEASURES: Tumor downstaging was evaluated. Local recurrence, distant metastases, and disease-free and overall survival were analyzed with the Kaplan-Meier method.RESULTS: A total of 101 patients accepted and 162 patients declined the modified preoperative radiotherapy regimen. Of the 101 patients receiving preoperative radiotherapy, 5 (5%) had a complete response, and 50 (50%) achieved TNM downstaging. The local recurrence rate was 5% with preoperative radiotherapy and 18% in the control groups (p = 0.02). Within the preoperative radiotherapy group, 5-year disease-free survival and overall survival rates were significantly higher in patients with T-, N-, or TNM-downstaging than in patients without downstaging. Evaluation of literature reports indicated that clinical safety and effectiveness of the modified protocol are comparable to results of standard neoadjuvant procedures.LIMITATIONS: The allocation to study groups was not randomized, and patient self-selection may have introduced bias, particularly because patients with greater financial means were more likely to choose to undergo the preoperative radiotherapy regimen.CONCLUSIONS: Compared with surgery alone, this modified preoperative radiotherapy regimen is associated with significantly reduced local recurrence and complication rates, with improved survival in patients who show downstaging. The modified protocol offers a clinical outcome equivalent to standard preoperative radiotherapy regimens while offering an alternative for increasing the flexibility of preoperative radiation regimens in China.

Feasibility Of Relatively Low Neoadjuvantradiation Doses For Locally Advanced Rectal Cancer: A Propensity Score-Matched Analysis

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Tumor pathological response and downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: comparison of two radiation dose schedules

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant radiotherapy for stages II-III rectal cancer: a Meta-analysis

Effects of neoadjuvant chemotherapy with or without intensity‐modulated radiotherapy for patients with rectal cancer

Prolonged Neoadjuvant Chemotherapy Without Radiation Versus Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Propensity Score Matched Study

Comparing Neoadjuvant Long-Course Chemoradiotherapy with Short-Course Radiotherapy in Rectal Cancer

Intermediate-Fraction Neoadjuvant Radiotherapy For Rectal Cancer

Neoadjuvant Radiotherapy Vs. Surgery Alone for Stage II/III Mid-Low Rectal Cancer with or Without High Risk Factors: A Multicenter Randomized Trial.

Image Guided Concomitant Dose Escalation Neoadjuvant Radiotherapy in Patients with Locally Advanced Mid-low Rectal Cancer

Preoperative short-course radiotherapy followed by consolidation chemotherapy for treatment with locally advanced rectal cancer: a meta-analysis

[Efficacy of neoadjuvant radiochemotherapy in treatment of locally advanced low rectal cancer]

Timing of Additional Neoadjuvant Chemotherapy in Patients with Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision

Management of Clinically Involved Lateral Lymph Node Metastasis in Locally Advanced Rectal Cancer: A Radiation Dose Escalation Study

[Role of neoadjuvant rectal score in prognosis and adjuvant chemotherapy decision-making in locally advanced rectal cancer following neoadjuvant short-course radiotherapy and consolidation chemotherapy].

Efficacy of Neoadjuvant CapeOX/mFOLFOX6 Without Radiation for Patients with Baseline Resectable Mid-Low Locally Advanced Rectal Cancer.

Prognostic Ability of the Neoadjuvant Rectal (NAR) Score in Long‐course Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer: a Retrospective Cohort Study

Neoadjuvant Radiotherapy Versus Surgery Alone for Stage II/III Mid-low Rectal Cancer with or Without High-risk Factors

Neoadjuvant Mfolfoxiri Chemotherapy-Improved Survival Benefit Comparing with CRT in Locally Advanced Rectal Cancer: A Propensity Score Matched Analysis from Two Prospective Trials.